Evidence map›Paper›PMID 35538033›Full record

ArticleActa biochimica et biophysica Sinica2022

CD82 palmitoylation site mutations at Cys5+Cys74 affect EGFR internalization and metabolism through recycling pathway.

Jingya Bu, Weiliang Zhong, Meixian Li, Shuiqing He, Mingzhe Zhang, Yu Zhang, Ying Li

Open access · diamondAbstract read
In one paragraph

Article in Acta biochimica et biophysica Sinica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Jingya BuDepartment of Clinical Laboratory, the Second Affiliated Hospital of Dalian Medical University, Dalian 116023, China.
Weiliang ZhongDepartment of Orthopaedics Surgery, the First Affiliated Hospital of Dalian Medical University, Dalian 116011, China.
Meixian LiDepartment of Clinical Laboratory, Jiangxi Maternal and Child Health Hospital, Nanchang 330000, China.
Shuiqing HeDepartment of Clinical Laboratory, the Second Affiliated Hospital of Dalian Medical University, Dalian 116023, China.
Mingzhe ZhangDepartment of Clinical Laboratory, the Second Affiliated Hospital of Dalian Medical University, Dalian 116023, China.
Yu ZhangDepartment of Clinical Laboratory, the Second Affiliated Hospital of Dalian Medical University, Dalian 116023, China.
Ying LiDepartment of Clinical Laboratory, the Second Affiliated Hospital of Dalian Medical University, Dalian 116023, China.
Dalian Medical University · CNJiangxi Maternal and Child Health Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tetraspanin CD82 often participates in regulating the function of epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (c-Met). Palmitoylation is a post-translational modification that contributes to tetraspanin web formation and affects tetraspanin-dependent cell signaling. However, the molecular mechanisms by which CD82 palmitoylation affects the localization and stability of EGFR and c-Met have not yet been elucidated. This study focuses on the expression and distribution of EGFR and c-Met in breast cancer as well as the related metabolic pathways and molecular mechanisms associated with different CD82 palmitoylation site mutations. The results show that CD82 with a palmitoylation mutation at Cys5+Cys74 can promote the internalization of EGFR. EGFR is internalized and strengthened by direct binding to CD82 with the tubulin assistance and located at the recycling endosome. After studying the recycling pathway marker proteins Rab11a and FIP2, we found that formation of the EGFR/CD82/Rab11a/FIP2 complex promotes the internalization and metabolism of EGFR through the recycling pathway and results in the re-expression of EGFR and CD82 on the cell membrane.

Indexed as

Kangai-1 ProteinLipoylationErbB ReceptorsMutationPhosphorylationErbB ReceptorsKangai-1 ProteinCD82EGFRpalmitoylationRab11atetraspanin

Identifiers

PMID35538033
PMCPMC9828285
OpenAlexW4214816648

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.